BioCentury
ARTICLE | Clinical News

RSLV-132: Phase I data

February 22, 2016 8:00 AM UTC

A double-blind, dose-escalation, U.S. Phase I trial in 22 evaluable patients with an SLE Disease Activity Index (SLEDAI) score of >0 points showed that a greater proportion of patients receiving 0.3-10 mg/kg doses of IV RSLV-132 given weekly or every 2 weeks for 4 weeks had an improvement in disease activity vs. placebo (44% vs. 33%). The frequency of adverse events was similar between treatment arms. The trial enrolled 32 patients with inactive to mild SLE. RSLV-132 is in a Phase IIa trial to treat lupus. ...